Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2005

View Archived Issues

Astressin-2B reduces enterotoxin-mediated inflammatory processes

SLV-317 exerts antiinflammatory effects in experimental ileitis and colitis

Chugai reports domestic and overseas progress

Updated results for Genasense in CLL

Animal data on SP-304

Bionomics receives grant extension for CNS drug development

Talotrexin enters new phase I/II study for ALL

New phase Ib/II study of ADH-1

Mera and Rincon announce protein expression system research collaboration

Sorafenib plus chemotherapy studied in new phase III trial

Low incidence of anemia found with viramidine plus peginterferon alfa-2a in hepatitis C patients

Good safety profile found for multiple doses of VX-950 in healthy subjects

New data on the safety and pharmacokinetics of CpG-10101 in hepatitis C

SCR-011, a therapeutic candidate for ocular neovascularization

MB-500 promotes corneal wound healing

Antisense hTERT shows potential as a gastric cancer therapy

Amarillo receives SBIR grant for H. pylori vaccine development work

New stem cell trial to begin in heart failure patients

Piperazine derivative shows anxiolytic and antidepressant activity in preclinical studies

Novel benzodiazepine derivatives possess prolonged anticonvulsant properties

Recent patents disclose novel therapeutic agents for cancer

Remicade approved for psoriatic arthritis

Traditional approval for Trizivir

Novel SERMs emerge from GlaxoSmithKline research

Vertex patents voltage-gated sodium channel inhibitors for treatment of pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.